Literature DB >> 1294431

[Prenatal diagnosis and therapy of adrenogenital syndrome with 21-hydroxylase deficiency].

H G Dörr1, W G Sippell, R P Willig.   

Abstract

Genetic counselling of the parents is prerequisite before prenatal diagnosis and prenatal therapy of CAH. Today, chorionic villous biopsy with DNA probe is the method of choice to identify homozygous CAH-fetuses. The aim of prenatal therapy is to prevent intrauterine virilization of the external genitalia in affected female fetuses. Therefore, dexamethasone (3 x 0.5 mg/d p.o.) is given to the mother immediately when pregnancy is confirmed, before prenatal diagnosis and karyotyping is possible. After the result of prenatal diagnosis, treatment is continued until term only when the fetus is affected and female. Prenatal diagnosis and effective treatment of female CAH fetuses greatly reduces the need for corrective surgery and thus helps to alleviate anxieties of prospective parents and therefore encourages further pregnancies. However, prenatal treatment of CAH to date still is an experimental therapy [corrected].

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1294431     DOI: 10.1055/s-2007-1023188

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  1 in total

1.  Experts' Opinion on the Prenatal Therapy of Congenital Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency - Guideline of DGKED in cooperation with DGGG (S1-Level, AWMF Registry No. 174/013, July 2015).

Authors:  H G Dörr; G Binder; N Reisch; U Gembruch; P G Oppelt; P Wieacker; J Kratzsch
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-12       Impact factor: 2.915

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.